← Back to Search

Ketone Body Supplement

Ketone Supplement for Colorectal Cancer Prevention (BHB-CRC Trial)

N/A
Waitlist Available
Led By Bryson W Katona, MD, PhD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age of 18 years or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, which will be approximately 2 years
Awards & highlights

BHB-CRC Trial Summary

This trial is testing whether a ketone supplement can help people undergoing a standard colonoscopy or sigmoidoscopy.

Who is the study for?
This trial is for adults over 18 who can consent and are scheduled for a standard colonoscopy or flexible sigmoidoscopy. It's not suitable for those with diabetes on medication, severe kidney disease, active cancer treatment, pregnancy, incarceration, under 18s, history of bowel diseases or recent fasting diets.Check my eligibility
What is being tested?
The study tests if taking β-hydroxybutyrate (BHB) supplement is feasible for people getting routine colon checks. BHB is thought to help in preventing colorectal cancer.See study design
What are the potential side effects?
Potential side effects of BHB supplementation may include gastrointestinal discomfort such as nausea or stomach pain. Since this is an initial investigation, other unexpected side effects might be observed.

BHB-CRC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

BHB-CRC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, which will be approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, which will be approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine whether oral BHB supplementation is safe and tolerable
Secondary outcome measures
Determine whether oral BHB supplementations increases serum BHB levels
Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa

BHB-CRC Trial Design

1Treatment groups
Experimental Treatment
Group I: BHB supplementationExperimental Treatment1 Intervention
Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,024 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
388 Previous Clinical Trials
145,649 Total Patients Enrolled
Bryson W Katona, MD, PhDPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
100 Total Patients Enrolled

Media Library

Colorectal Cancer Clinical Trial 2023: R-1,3-Butanediol Highlights & Side Effects. Trial Name: NCT05338307 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for enrollment in this experiment?

"According to the clinical trial registry, this study is still enrolling participants. The project was initially announced on April 19th 2022 and updated for the last time a week later."

Answered by AI

What is the enrollment capacity for this medical experiment?

"Affirmative. According to the clinicaltrials.gov portal, this experiment is still searching for suitable participants. The trial was publicly announced on April 19th 2022 and it's requirements were updated recently on April 26th 2022; requiring 20 individuals from a single trial site."

Answered by AI
~7 spots leftby May 2025